Unknown

Dataset Information

0

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100?units/mL.


ABSTRACT: AIM:Treat-to-target, randomized controlled trials have confirmed lower rates of hypoglycaemia at equivalent glycaemic control with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 1 (T1D) or type 2 diabetes (T2D). Treat-to-target trials are designed to enable comparisons of safety and tolerability at a similar HbA1c level. In this post hoc analysis of the SWITCH 1 and 2 trials, we utilised a patient-level modelling approach to compare how glycaemic control might differ between basal insulins at a similar rate of hypoglycaemia. MATERIALS AND METHODS:Data for HbA1c and symptomatic hypoglycaemia from the SWITCH 1 and SWITCH 2 trials were analyzed separately for patients with type 1 diabetes and type 2 diabetes, respectively. The association between the individual patient-level risk of hypoglycaemia and HbA1c was investigated using a Poisson regression model and used to estimate potential differences in glycaemic control with degludec versus glargine U100, at the same rate of hypoglycaemia. RESULTS:Improvements in glycaemic control increased the incidence of hypoglycaemia with both basal insulins across diabetes types. Our analysis suggests that patients could achieve a mean HbA1c reduction of 0.70 [0.05; 2.20]95% CI (for type 1 diabetes) or 0.96 [0.39; 1.99]95% CI (for type 2 diabetes) percentage points (8 [1; 24]95% CI or 10 [4; 22]95% CI mmol/mol, respectively) further with degludec than with glargine U100 before incurring an equivalent risk of hypoglycaemia. CONCLUSION:Our findings suggest that patients in clinical practice may be able to achieve lower glycaemia targets with degludec versus glargine U100, before incurring an equivalent risk of hypoglycaemia.

SUBMITTER: Philis-Tsimikas A 

PROVIDER: S-EPMC7186831 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.

Philis-Tsimikas Athena A   Lane Wendy W   Pedersen-Bjergaard Ulrik U   Wysham Carol C   Bardtrum Lars L   Harring Signe S   Heller Simon S  

Diabetes, obesity & metabolism 20200124 5


<h4>Aim</h4>Treat-to-target, randomized controlled trials have confirmed lower rates of hypoglycaemia at equivalent glycaemic control with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 1 (T1D) or type 2 diabetes (T2D). Treat-to-target trials are designed to enable comparisons of safety and tolerability at a similar HbA1c level. In this post hoc analysis of the SWITCH 1 and 2 trials, we utilised a patient-level modelling approach to compare  ...[more]

Similar Datasets

| S-EPMC7064957 | biostudies-literature
| S-EPMC8252805 | biostudies-literature
| S-EPMC7261296 | biostudies-literature
| S-EPMC6594069 | biostudies-literature
| S-EPMC5391813 | biostudies-literature
| S-EPMC6618106 | biostudies-literature
| S-EPMC7407002 | biostudies-literature
| S-EPMC4237557 | biostudies-literature
| S-EPMC6771831 | biostudies-other
| S-EPMC7305011 | biostudies-literature